Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.

BACKGROUND & AIMS Danoprevir (RG7227; ITMN-191) is a potent inhibitor of the HCV NS3/4A serine protease. The aims of this double-blind, placebo-controlled, multiple-ascending dose phase Ib study were to evaluate safety, tolerability, antiviral activity, resistance, and pharmacokinetics of once- and twice-daily danoprevir in the presence of low-dose ritonavir (danoprevir/r) and in combination with peginterferon alfa-2a (40KD)/ribavirin in treatment-naive HCV genotype 1 patients. METHODS Thirty eligible patients were enrolled into three cohorts and treated with danoprevir/r or placebo/r all in combination with peginterferon alfa-2a (40KD)/ribavirin for 15 days. Cohort 1 received danoprevir/r at 100/100mg twice daily; Cohort 2 200/100mg once daily; and Cohort 3 200/100mg twice daily. RESULTS The median reductions in HCV RNA from baseline after 14 days of treatment (day 15) were -5.1, -4.8, and -4.6 log(10)IU/ml in Cohorts 1, 2, and 3, respectively, and -2.7 log(10) in placebo/r and peginterferon alfa-2a (40KD)/ribavirin recipients. Viral breakthrough was not observed in any patient. On day 15, HCV RNA was undetectable (<15IU/ml) in 6/9 (67%), 4/8 (50%), and 8/8 (100%) patients in Cohorts 1, 2, and 3, respectively. When co-administered with low dose ritonavir, danoprevir concentrations reached a steady state between 6 to 10 days of dosing. Danoprevir exposures increased more than dose proportionally between 100/100mg and 200/100mg. Danoprevir/r plus peginterferon alfa-2a (40KD)/ribavirin was well-tolerated with no safety-related discontinuations. CONCLUSIONS Danoprevir/r plus peginterferon alfa-2a (40KD)/ribavirin provides profound and robust reductions in serum HCV RNA, at substantially lower systemic exposures compared to those observed with higher doses of danoprevir in the absence of ritonavir. These results support further studies of danoprevir/r.

[1]  M. Manns,et al.  Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. , 2009, Current opinion in investigational drugs.

[2]  Dylan P. Hartley,et al.  Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227) , 2008, Antimicrobial Agents and Chemotherapy.

[3]  M. Manns,et al.  Telaprevir for previously treated chronic HCV infection. , 2010, The New England journal of medicine.

[4]  Tara L. Kieffer,et al.  Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.

[5]  B. Brandhuber,et al.  Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. , 2009, Biochemistry.

[6]  Patrick F. Smith,et al.  753 IMPACT OF LOW DOSE RITONAVIR BOOSTING ON THE PHARMACOKINETICS OF RG7227 (ITMN-191), A HIGHLY POTENT AND SELECTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE , 2010 .

[7]  M. Foisy,et al.  Induction Effects of Ritonavir: Implications for Drug Interactions , 2008, The Annals of pharmacotherapy.

[8]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[9]  D. Harnois.  Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection , 2009 .

[10]  Todd M. Allen,et al.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.

[11]  J. McHutchison,et al.  Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. , 2008, Journal of hepatology.

[12]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[13]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[14]  Jean-Michel Pawlotsky,et al.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.

[15]  X. Tong,et al.  Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients , 2010, Hepatology.

[16]  S. Khoo,et al.  Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. , 2010, Antiviral research.

[17]  X. Forns,et al.  Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. , 2004, Gastroenterology.